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EDITORIAL REVIEW
Angiotensin actions in the kidney: Renewed insight into the
old hormone
Since the recognition of its potent vasoconstrictor action in
the renal circulation, angiotensin II (Ang II) has several times
come into the forefront in the nephrology community by
revealing new biological actions which are seemingly unrelated
to any of its previously recognized actions. Many of these
actions have now been extensively studied (Table 1). Of inter-
est, also, are its non-renal actions which are now known to be
similarly rich in variety, thanks to extensive investigations on
the central nervous and other organ systems.
This article overviews our most recent understanding of the
diversified renal actions of angiotensin II, including some
drastically revised data. While some of the actions have been
more extensively studied, conclusions regarding the implica-
tions of other actions await development of more precise
experimental methodologies. Thus, it is difficult to establish the
local level of endogenous angiotensin II in in situ settings,
hence, it is also difficult to employ "physiologic" concentra-
tions in experiments with certainty. Additionally, pharmaco-
logic blockade of angiotensin II to study the role of endogenous
angiotensin II may provoke activation of other systems, and the
state of angiotensin II blockade cannot necessarily be equated
totally with the absence of endogenous angiotensin II action.
Renal blood flow and glomerular filtration rate
Vascular smooth muscle contraction [1] and release of aldo-
sterone from the adrenal gland [2] were the first recognized
biologic actions of angiotensin II. Likewise, within the kidney,
Ang II was first recognized as a renal vasoconstrictor and,
indirectly through aldosterone, as a salt retaining hormone
acting on the renal tubule.
All three potential regulatory sites of the glomerular micro-
circulation—afferent and efferent arterioles and glomerular cap-
illary ultrafiltration coefficient (K)—have been documented as
targets for the constrictor action of Ang II. Numerous investi-
gators have demonstrated specific 1251 AngII binding to isolated
glomeruli and, in autoradiographic studies, have localized ra-
dioactivity to mesangial cells [3, 4]. Although afferent and
efferent arteriolar resistances are modulated by Ang II (dis-
cussed below), autoradiographic analysis has not successfully
demonstrated a high density of receptors on the arterioles [4].
In general, constriction of the afferent arteriole, or precapil-
lary sphincter, depresses not only the rate of plasma entering
the glomerulus (QA) but also the pressure within the down-
stream glonierular capillary (PGC). In contrast, constriction of
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the efferent arteriole (or postcapillary sphincter), although
depressing QA, raises Gc• When the efferent arteriole selec-
tively constricts, therefore, GFR is expected to be well pre-
served or even increased despite a fall in QA; hence, the
filtration fraction increases. In view of these contrasting effects
on P6 by changes in afferent and efferent arteriolar constric-
tion, the marked elevation in filtration fraction often seen with
exogenous Ang II administration (and fall in filtration fraction
during pharmacologic blockade of Ang II) was taken as evi-
dence for a preferential effect of Ang II on the efferent over the
afferent arteriole [5—7]. However, as discussed elsewhere [8],
an increase in the filtration fraction can occur with simultaneous
constriction of both arterioles. Although some in vivo [9] and in
vitro studies [10, 11] conducted thus far indicate that in normal
circumstances the efferent arteriole, compared to the afferent
arteriole, is more sensitive to the constrictive effect of angio-
tensin II, others [12, 13] contrastingly suggest that the primary
target of angiotensin II resides in the afferent arteriole. Apart
from this feverishly debated issue, it is of interest that some
pathophysiologic conditions are characterized by an augmented
sensitivity of the afferent arteriole to angiotensin II. Thus, in
Munich-Wistar rats with chronic extracellular fluid volume
depletion, in which a very high local level of angiotensin II is
achieved, exogenous administration of angiotensin II caused a
dramatic increase in afferent arteriolar resistance and a fall in
GFR [14], a phenomenon not seen during well-hydrated condi-
tions in the same strain of rat.
Modulation of glomerular capillary ultrafiltration coefficient
(Kf) is the third mechanism by which angiotensin II affects the
glomerular filtration rate [15]. It provides a mechanism through
which angiotensin influences GFR without necessarily compro-
mising QA (such as, decrease in filtration fraction). Many
vasoconstrictors capable of reducing K have also been shown
to induce morphologic appearance of contraction in mesangial
cells. Mesangial cells are endowed with myosin filaments and,
like vascular smooth muscle cells [16], respond with phosphor-
ylation and apparent contraction of myosin light chain in
response to Ang II and other vasoconstrictors [17]. Further-
more, Ang II opens calcium-activated chloride channels in
cultured rat mesangial cells [18]. On the basis of these obser-
vations, it is currently speculated that this contractile property
of the mesangium is linked to in vivo modulation of K. A recent
preliminary study [19] demonstrated a mechanistic relationship
between mesangial contraction and reduction in glomerular
surface area in vivo. This was done by planimetric assessment
of tissue specimens perfusion-fixed during exposure of specific
populations of glomeruli to Ang II infused through a branch of
the main renal artery. The difference between the area of the
total glomerular cross section and the total open capillary
network on perfusion-fixed tissues was taken as a parameter for
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Table 1. Established and proposed modes of angiotensin II actions in
the kidney
Vascular effect
1. Renal blood flow and or GFR
2. Glomerular sieving function (proteinuria)3. f Circulating cell entrapment4. t Mesangial macromolecular processing5. t Cell hypertrophy
6. Extrancellular matrix production (sclerosis)
7. C Tubuloglomerular feedback
Tubular effect
1. Na-H antiporter activity
2. Ammoniagenesis and gluconeogenesis
3. Cell hypertrophy
Interaction with other vasoactive agents
1. Cyclooxygenase activity2. [ Neurotransmitter release
3. Interaction with other peptides
mesangial contraction. When compared to glomeruli not ex-
posed to Ang II, glomeruli exposed to Ang II were found to
have reduced "open capillary area", lending support to the
notion that the reduction in Ang Il-induced K1 was accompa-
nied by a reduced filtering surface area which, in turn, was
associated with reduced "mesangial area".
While constrictive responses of each of the three effector
sites within the renal cortical microcirculation have unique and
often directly opposing influences on GFR (Fig. 1), the magni-
tude of the constrictor effect of Ang II on these targets is not
constant among different pathophysiologic states. The reasons
for this variability remain largely unknown, but it is because of
this variability that pharmacologic blockade of Ang II action
results in increased [6, 20—26], decreased [27], or unchanged
[28—30] GFR. During systemic hypotension, beneficial effects
on the GFR reflect Ang II's predominant actions on the efferent
arteriole. Kidneys faced with moderate reductions in systemic
blood pressure respond not only with the autoregulatory dila-
tation of the afferent arteriole but also with an Ang Il-mediated
constriction of the efferent arteriole, which protects P from
falling. Attenuation of this constrictive response of the efferent
arteriole by pharmacologic blockade of Ang II has been uni-
formly shown to result in profound fall in GFR [31, 32].
Profound constrictor action of angiotensin II on the afferent
arteriole, which compromises GFR, is seen in both volume
depletion and congestive heart failure. Thus, administration of
saralasin, an Ang II receptor antagonist, in acutely [18] as well
as chronically [33] volume depleted rats, has been shown to
cause relatively selective renal vasodilation (without systemic
hypotension) with parallel reductions in afferent and efferent
arteriolar resistances. In both animals and humans with conges-
tive heart failure, converting enzyme inhibition has been shown
to raise GFR [6, 25]. The profound influence of angiotensin II
on Kf, which contributes to the prevailing low level of GFR, has
been shown in several experimental settings. These include
volume depletion [14, 20, 41], renal vein obstruction [28],
renovascular hypertension [42], congestive heart failure [6], and
(possibly) urinary tract obstruction [43, 44]. However, other
low GFR states appear independent of appreciable constrictor
influence of Ang II on the glomerular circulation. These include
glomerulonephritis [45, 46], most forms of acute renal failure
(except for some specific experimental settings) [33], and
chronic renal disease.' When low GFR occurs in association
with low K1, reduced glomerular plasma flow is also typically
present, which often makes it difficult to quantitate the relative
importance of the low K1 in depressed GFR.2 Nevertheless, in
an animal model of minimal change nephrotic syndrome in
which the renin-angiotensin system is locally activated [47], an
angiotensin II receptor antagonist, saralasin, increased GFR in
association with amelioration in the markedly low level of K1
without appreciably affecting arteriolar resistances [39]. This
condition represents a unique circumstance in which an impor-
tant regulatory role of Kf on GFR has been demonstrated.
Angiotensin II infusion has long been recognized to increase
urinary prostaglandin levels, and studies with isolated glomeruli
and cultured cells of glomerular origin have demonstrated
increases in prostaglandin production [48, 49]. Since it is well
recognized that cyclooxygenase inhibition augments Ang II-
mediated decreases in renal blood flow and GFR [50], it is
currently thought that angiotensin-induced production of gb-
merular vasodilatory prostaglandins serves to modulate the
constrictive actions of Ang lIES!].
Tubuloglomerular feedback mechanism
Signals related to changes in tubule fluid ions reaching the
macula densa cells of the ascending loop of Henle are transmit-
ted to the vascular structures of the nephron to alter the local
vasomotor tone and hence GFR. Thus, a remarkably constant
rate of salt delivery to the distal segments of the nephron can be
achieved, creating a situation in which reabsorption is precisely
regulated to maintain body fluid balance. When angiotensin II
was first recognized as a local hormone released from specific
vascular structures within the afferent arteriole [that is, juxta-
gbomerular apparatus (JGA)] in proximity to the macula densa,
it was postulated that Ang II mediated this tubuloglomerular
feedback (TGF) mechanism [52, 53]. This hypothesis proposed
that Ang II released from JGA is capable of regulating the local
glomerular vasomotor tone, and hence GFR, which is therefore
under the control of salt delivery to the macula densa. How-
ever, this hypothesis has not held up to experimental scrutiny
'While chronic administration of an angiotensin I converting enzyme
inhibitor has been repeatedly shown to reduce systemic and glomerular
pressure in chronic renal disease models [34], including diabetic
nephropathy [35], acute pharmacologic inhibition of angiotensin II
regularly [36], although not uniformly [37], has failed to affect systemic
or intrarenal hemodynamics. This raises the interesting possibility that
Ang II can cause hypertension through inducing the hypertrophy of
resistance vessels. Thus, in this setting, only chronic—but not acute—
inhibition of Ang II can prevent/reverse hypertension.
2 For reasons beyond the scope of the current discussion, a reduction
in Kf is expected to lead to a proportionally lesser degree of reduction
in GFR. For this reason, it has been argued that a reduction in K1 in
many experimental settings has a relatively minor impact on GFR [38].
Nevertheless, a few experimental circumstances [39, 40] have been
presented showing major importance for altered K1 in GFR determina-
tion. Given that a marked reduction in Kf leads to a fall in filtration
fraction and that such pathophysiologic settings as those characterized
by a severe depression in GFR (which are commonly unsuitable for
experimental assessment of GFR determinants) are more commonly
characterized by a reduction in filtration fraction, K1 appears to be a
major regulator of GFR in pathologic, but not necessarily physiologic,
conditions.
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Fig. 1. Effector sites of angiotensin II within
the glomerular microcirculation. The
constrictor action of angiotensin II raises
afferent (RA) and efferent arteriolar (RE)
resistances and reduces the glomerular
capillary ultrafiltration coefficient (Kr). While
increase in RA and reduction in K tend to
reduce glomerular filtration rate, an increase
in RE, in some circumstances, serves to raise
(or prevent reduction in ) GFR. The
magnitude of the constrictor effect of
angiotensin II on these targets is not uniform
among different pathophysiologic states for
reasons largely unknown, the net effect of
angiotensin II being to raise, lower, or have
no impact on GFR. For the clarification of the
issue, accuracy in anatomical detail is
sacrificed in this diagram.
and is currently considered obsolete; for example, in volume
depletion, a condition in which salt delivery to the macula densa
is reduced, the hypothesis would predict suppression of local
release of angiotensin II, rather than the enhanced renin secre-
tion that has been noted [54, 55]. Moreover, SkØtt and Briggs
[56], using an isolated perfused and superfused juxtaglomerular
apparatus, have demonstrated a negative, instead of positive,
relationship between the sodium chloride concentration at the
macula densa and renin secretion.
Although Ang II does not appear to mediate the tubulo-
glomerular feedback mechanism, it appears to play an impor-
tant permissive role in the operation of the mechanism. Thus,
pharmacologic blockade of angiotensin II action has been
shown to abrogate the feedback responsiveness [57—59]. Fur-
thermore, administration of Ang II has restored the feedback
responsiveness in rats given a converting enzyme inhibitor [60]
and enhanced it in normal unmanipulated rats [61, 62]. The
mechanism involved in the regulation of the sensitivity of the
feedback response by Ang II remains uncertain. It is theoreti-
cally possible—although entirely speculative—that Ang II, by
acting as an intracellular hormone (whose production, action,
and degradation occur within the effector cells), mediates TGF.
In this postulate, renin and Ang II levels in the extracellular
fluid have little relevance to their intracellular level or activity.
Glomerular sieving function and proteinuria
Pickering and Pnnzmetal reported a half century ago that
intravenous renin administration in the rabbit caused a substan-
tial increase in urinary protein excretion, along with natriuresis
and chloriduria [63]. Since this pioneering observation, renin or
angiotensin has been repeatedly shown to enhance urinary
protein excretion [15, 64—69]. It was initially speculated that the
proteinuric effect of renin is secondary to suppression of tubular
reabsorption of protein [69]. Although the quantitative impor-
tance of potentially altered tubule protein reabsorption in the
renin/angiotensin-induced proteinuria still remains uncertain,
two experimental approaches provide convincing evidence in-
dicating that the proteinuria involves increased passage of
protein through the glomerular capillary wall [66, 67]. Using an
electron-dense macromolecule tracer, saccharated ferric oxide
(SF0), electron microscopic studies by Deodhar, Cuppage and
Gableman [66] demonstrated that rats given renin had a marked
shift in localization of SF0 from the capillary lumen and lamina
rara interna of the glomerular basement membrane to lamina
rara externa and Bowman's space. Subsequently, micropucture
collection of glomerular filtrate from surface nephrons of
Munich-Wistar rats, performed by Eisenbach, Van Liew and
Boylan [67], revealed some 25-fold increase in albumin filtration
at the single glomerular level, while whole kidney total protein
excretion increased only threefold during intravenous infusion
of angiotensin. Although such an increase in macromolecular
traffic across the capillary wall was taken to reflect altered
permeability properties of the glomerular basement membrane
to macromolecules [66], other factors extrinsic to the capillary
wall could account for the renin/angiotensin-induced altered
glomerular sieving function.
The Kedem-Katchalsky fonnulation, a hydrodynamic theory
of solute transport through pores, states that any macromolec-
ular transport across a semipermeable membrane placed in fluid
phase is governed by two forces, namely, convective force and
diffusive force. For transport across the glomerular capillary
wall, the former is derived by volume flux, that is, filtration rate
of water containing dissolved macromolecules, and the latter by
the profile of macromolecule concentrations within the plasma
along the glomerular capillary. In this regard, angiotensin II has
the capacity to amplify both forces: the former by raising
glomerular capillary hydraulic pressure and the latter by in-
creasing the plasma macromolecular concentration within the
glomerular capillary, which typically occurs with increased
filtration fraction. Indeed, based on the observation that intra-
venous administration of angiotensin II in rats causes protein-
uria and glomerular macromolecular flux together with a
marked increase in filtration fraction (without affecting volume
flux or GFR), the proteinuric effect of angiotensin II was
attributed to its hemodynamic effect [64].
Previously, the glomerular wall permeability property and the
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Fig. 2. Schematic presentation of the relationship among glomerular
capillary pressure (PGC)' functional pores in the glomerular capillary
wall, and glomerular macromolecular sieving, which is postulated on
the bases of experimental data and calculations. In contrast to normal
steady state condition (top), the high local level of endogenous angio-
tensin II (middle) caused by renal vein constriction drastically raises
Pc' which, in turn, increases non-size selective pores on the capillary
wall, thereby allowing the bulk of macromolecules to escape into the
Bowman's space and into the urine. When the high P0 was largely
attenuated by saralasin (bottom), an angiotensin II receptor antagonist,
the abnormal presence of a large number of non-selective pores and the
sieving defect were largely corrected. The imaging study of Steinhousen
et al, as well as our perfusion fixation experiment (Fed Proc 42:3075,
1983), document that the dimension of the glomerular capillary lumen is
unevenly affected. Thus, Ang II is thought to induce both reduced total
filtering surface area (that is, Kf) and increased nonselective pores
through stretching, as illustrated in this figure.
hemodynamic parameters were regarded as separate and inde-
pendent entities, with the glomerular wall permeability pre-
sumed unaffected by angiotensin II. Yoshioka et al [281 added a
new dimension to our understanding of the kinetics involved in
angiotensin-induced proteinuria, identifying the role for endog-
enous angiotensin. In their study, an acute partial renal vein
constriction (RVC) in Munich-Wistar rats caused a marked
elevation in the glomerular transcapillary hydraulic pressure
difference and efferent arteriolar resistance. These changes
were associated with a marked increase in urinary protein
excretion and fractional clearances of neutral [125J] dextrans
(CDEX/CIN) for large dextrans ( 44 A) but not for small
dextrans ( 42 A). Intravenous infusion of an angiotensin II
antagonist, saralasin, largely and promptly normalized these
indices, including glomerular capillary pressure, sieving defect
and membrane pore abnormalities, despite continued RVC. On
the basis of the heteroporous membrane theory of glomerular
filtration, the glomerular sieving defect during RYC was attrib-
uted to an increase in the relative fluid flux through a group of
large non-selective pores. A marked elevation in glomerular
capillary pressure induced by enhanced constrictive action of
endogenous angiotensin II on the efferent arteriole, in turn,
accounts largely for the abnormally large population of large
non-selective pores in the glomerular capillary wall during RVC
(Fig. 2).
These observations make necessary a revision in the view of
the mechanism underlying the glomerular sieving defect in
various settings and indicate that the two parameters determin-
ing glomerular sieving function, membrane property and hemo-
dynamic factors, are not independent and that the membrane
size selectivity property is under the influence of the ambient
glomerular capillary pressure acting on the membrane. This
notion has been supported in other experimental settings, for
example, acute phase of immune complex glomerulonephritis
[45], chronic progressive renal disease [36], and human protein-
uria [45]. This raises an interesting possibility that, in clinical
settings, angiotensin converting enzyme inhibitor (ACEI)-in-
duced reductions in proteinuria may, in part, be secondary to
reductions in the large non-selective pores that occur concom-
itantly with reductions in glomerular capillary pressure, a
phenomenon independent of ACEI's potentially salutary effect
on the glomerular structure.
It should be noted, however, that human studies have yet to
show convincingly that angiotensin is causally linked to devel-
opment of proteinuria. Studies testing the effect of exogenous
angiotensin II have instead shown reduced proteinuria in asso-
ciation with a fall in GFR (that is, reduced convective forces)
[70].
Mesangial macromolecular processing
Farquhar and Palade [71] were the first to document the
distinct morphologic and functional characteristics of glomeru-
lar mesangial cells, separating them from epithelial or endothe-
hal cells. On the basis of the localization of exogenously
injected ferritin in the subendothelial space and cytosohic com-
partment of mesangial cells, they proposed cellular phagocytic
functions in the removal of "filtration residue" from the circu-
lation. In agreement with this proposal, Camazine et al [72]
obtained a population of glomerular cells from freshly isolated
glomeruli that were highly phagocytic for opsonized Zymosan
particles and had the potential to develop Fc and C3 receptors.
While it remains conceivable that the phagocytic cells represent
a special subpopulation of marrow-derived cells present in the
mesangial region [73], the cells possessing phagocytic ability
may represent a distinctive fraction of resident mesangial cells
that bear Ia determinants [74]. In any case, these phagocytic
mesangial cells are believed to function as a local reticuloen-
dothelial system and to play a major role in the deposition or
removal of immune complex. Thus, in the study of Michael,
Fish and Good [75] with aggregated human gamma globulin, a
polydisperse population of macromolecules having many of the
properties of antigen-antibody complexes localized in the
mouse glomerulus after intravenous injection. Within a few
hours, transport of these aggregates into the mesangial region
was noted, with gradual disappearance over the next 36 to 72
hours. Of further interest, analogous to neutrophils and macro-
phages, phagocytosis of opsonized particles by cultured rat
mesangial cells results in an oxidative burst with generation of
superoxide anion and hydrogen peroxide, and in the stimulation
of the lipoxygenase pathway of arachidonic acid metabolism
[76]. Likewise, colloidal gold particles (10 nm diameter) coated
with fresh serum are endocytosed by cultured mesangial cells
and delivered to their lysosomes in association with stimulation
of PGE2 production [77]. Of particular interest, preincubation
of mesangial cells with Ang II resulted in enhanced uptake of
gold particles coated with IgG2b. In contrast, ANP, dopamine,
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and dibutyryl cAMP were found to attenuate the uptake [781.
These findings echo previous observations in vivo that Ang II
given exogenously increases mesangial uptake and delays clear-
ance from the mesangium of tracer macromolecules in normal
rats [79—81] and are reminiscent of earlier findings that Ang II
increases phagocytic activity of macrophages [82—841. The
enhanced phagocytic action of macrophages induced by Ang II
was found not to be associated with enhanced release of oxygen
radical metabolites [831.
Evidence supporting the notion that promotion of mesangial
phagocytic action by Ang II may have pathophysiologic impor-
tance is found in two separate studies in an animal model of
puromycin aminonucleoside- (PAN-) induced nephrosis. Thus,
while mesangial macromolecular uptake was shown to be
increased in PAN rats [851, the enhanced mesangial uptake of
radiolabeled, heat-aggregated IgG in PAN rats was nullified by
an acute infusion of saralasin (300 jg/kg/min) [86]. PAN rats,
which are characterized by glomerular morphologic changes
indistinguishable from human minimal change disease in the
early stage, develop mesangial lesions typically seen in the late
stages of focal glomerular sclerosis [87, 88]. Recent findings in
PAN rats that oral administration of an angiotensin I converting
enzyme inhibitor markedly attenuates progression of glomeru-
lar lesions to focal glomerular sclerosis [89] are consistent with
the possibility that enhanced macromolecular deposition (sec-
ondary to enhanced Ang II action) and phagocytosis by mesan-
gial cells form a crucial intermediary step leading to glomerular
sclerosis [90, 91]. It should be noted, however, that it is
methodologically not possible in the above in vivo morphologic
studies to evaluate the relative importance of mesangial phago-
cytosis from matrix entrapment. In this regard, pharmacologic
manipulations of angiotensin action can affect both of these
processes.
Tubule transport
In addition to its well known effects upon the microcircula-
tion, it has become increasingly apparent that angiotensin II
serves an important function as a modulator of proximal tubule
reabsorption. Receptors for Ang II have been localized to both
basolateral and apical membranes of the proximal tubule [92—
96]. In contrast to giomerular Ang II receptors [97], proximal
tubule Ang II receptor density is increased with sodium deple-
tion and decreased with sodium loading or mineralocorticoid
administration [95]. Brown and Douglas have suggested that
transmembrane electrical potential difference may also affect
Ang II binding to brush border receptors [98].
Angiotensin converting enzyme also exists in high concentra-
tions in the proximal tubule [99]. Immunohistochemical local-
ization of angioten sin I converting enzyme (ACE) has indicated
progressive increases in activity from Si to S3 and from outer
cortex to inner cortex and outer medulla [99, 100]. ACE has
been localized to both apical and basolateral membranes of the
proximal tubule, although brush border membranes appear to
contain higher concentrations [101, 102]. Of interest, recent
studies using in situ hybridization have localized angiotensino-
gen mRNA to the proximal tubule [103]. Similar to proximal
tubule Ang II receptors, proximal tubule angiotensinogen
mRNA increases with sodium depletion. Thus, it is possible
that local production of angiotensin II may modulate proximal
tubule function [104, 105]; in addition, androgen administration
upregulates renal cortical angiotensinogen mRNA expression
[105].
That Ang II can influence proximal tubule function is now
well established, although early micropuncture studies pro-
duced conflicting results, with evidence for stimulation, inhibi-
tion, or no effect upon solute and water disposition. The
landmark study of Harris and Young [106], utilizing stationary
split droplet microperfusion with simultaneous peritubular cap-
illary perfusion, unequivocally demonstrated effects of Ang II
upon proximal tubule (S2) reabsorption. In these studies, l0—'
M to 10—10 M led to stimulation of proximal tubule reabsorption
while  lO M inhibited proximal fluid reabsorption.
Subsequent studies in the rabbit isolated perfused proximal
tubule by Schuster, Kokko and Jacobson confirmed this bipha-
sic effect of Ang II and clearly demonstrated that, unlike the
intestine in which modulation of volume reabsorption is due to
angiotensin-induced increases in alpha adrenergic neurotrans-
mitter release, angiotensin II exerts its effects directly in the
proximal tubule [107].
More recent micropuncture studies by Liu and Cogan have
indicated that, in the early Si segment of the proximal tubule,
Ang II is an extremely potent stimulator of Na-H exchange
and bicarbonate reabsorption, possibly regulating as much as
60% of bicarbonate reabsorption in this segment [108, 109].
They have estimated that Ang II could thus modulate as much
as 30% of total renal hydrogen ion secretion [108, 109]. In
addition, these researchers have demonstrated that early 51
segments also contained the highest concentration of angioten-
sin II binding sites. Although brush border binding of Ang II
was once thought to reflect degradation of filtered hormone
[110], numerous studies indicate that the brush border binding
sites represent functional receptors and that luminal infusion of
Ang II will modulate proximal tubule reabsorption [93, 111—
113].
Schuster et al [107] had previously determined that the Ang II
stimulation of fluid reabsorption occurred by stimulation of
electroneutral processes, and subsequent studies have demon-
strated that the increased bicarbonate reabsorption is mediated
by stimulation of the electroneutral NafH exchange [108,
109]. It is of interest that in cultured smooth muscle cells, Ang
II stimulates Na/H by the apparently novel mechanism of
increasing the affinity of the external Na binding site [114].
However, a recent study in suspension of rat proximal tubules
did not find evidence for alteration in Na affinity as the
mechanism for stimulation of Na/H exchange by 10 M
Ang II [48]. The micropuncture studies of Liu and Cogan in
early rat proximal convoluted tubules (PCT) are in general
agreement with the observations of Schuster et a! in isolated
rabbit PCT; however, in addition to direct tubular effects upon
bicarbonate reabsorption, Liu and Cogan have determined that
Ang Il-stimulated NaCl reabsorption is also mediated by acti-
vation of presynaptic Ang II receptors that initiate catechol-
amine release from renal nerves [108]. Evidence that endoge-
nous angiotensin II, indeed, plays an important regulatory role
in determining proximal tubule reabsorption in physiologic
settings was obtained in a rat model of congestive heart failure
[116]. Rats with congestive heart failure induced by surgical
creation of myocardial infarction had markedly elevated levels
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Fig. 3. Effect of angiotensin ii on proximal
tubule transport. Angiotensin II, through
specific receptor systems present in both post-
glomerular vascular smooth muscle cells (that
is, efferent arteriole) and proximal tubule
epithelial cells, regulates not only the
transepithelial fluid transport but also the
transcapillary fluid transport. Given that these
two transport processes are series-linked,
angiotensin II is regarded as a highly efficient
regulator for net proximal fluid transport. As
detailed in Footnote 3, endogenous Ang II is
geared to raise fractional fluid reabsorption. In
conditions where renal plasma flow and GFR
are low, endogenous Ang II serves to
counteract against the tendency of proximal
reabsorption to fall (in keeping with
maintenance of glomerulotubular balance) by
activating Na/H antiporter and raising
peritubular capillary oncotic pressure.
of fractional proximal reabsorption, but absolute proximal
reabsorption was unchanged, as predicted earlier. However,
acute administration of an angiotensin converting enzyme in-
hibitor was shown to normalize this abnormal proximal reab-
sorption and to blunt the sodium retention [115]. Considering
that proximal fluid reabsorption is a series-linked process, that
is, transport from tubule lumen to interstitium and then inter-
stitium to peritubular capillary compartment, it was apparent
that Ang Ii's action is geared to enhance fractional (and not
necessarily absolute) proximal reabsorption, by acting on both
of these processes. The former is accomplished by activating
Na/H co-transport in the proximal tubule, while the latter
occurs by inducing preferential constriction of the efferent
arteriole, thereby effecting a high filtration fraction.3 The result-
Variations in glomerular filtration which occur within normal phys-
iologic and pathophysiologic conditions are regularly accompanied by
roughly proportional changes in the rate of fluid reabsorbed by the
proximal tubule [117—125]. This phenomenon, or maintenance of glom-
erulotubular balance (GTB), is achieved by the orchestrated adjust-
ments in both transepithelial and peritubular transcapillary fluid transfer
mechanisms.
Transepithelial transfer. The rate of fluid delivery to the proximal
tubule is believed to affect the rate of fluid reabsorbed across the
proximal tubule. It has been proposed that the quantity of filtered
bicarbonate serves to achieve quantitatively proportional proximal fluid
reabsorption [126—133]. The mechanisms for this bicarbonate transport
appear to be linked to active proton secretion—most if not all of which
is believed due to Na/H exchange [195]. Delivery of bicarbonate to
the proximal tubule assures the proportional net bicarbonate reabsorp-
tion not only by modulating the luminal bicarbonate concentration
(thereby determining bicarbonate backdiffusion into the tubule lumen)
but also by affecting the activity of the transport system [135, 136].
Peritubular transcapilla,y transfer. Mechanisms regulating fluid
transfer across the peritubular capillary are also designed to contribute
to GTB. Due to mechanisms discussed elsewhere, variations in glomer-
ular filtration rate occur in a highly plasma flow-dependent manner
[137], that is, the filtration fraction or the ratio between GFR and renal
plasma flow rate remains remarkably constant from condition to con-
ant increased peritubular capillary oncotic pressure offsets the
influence of reduced peritubular capillary surface area (second-
ary to the low plasma flow [116]), which would otherwise be
dition. This indicates that some factor or factors other than peritubular
capillary plasma oncotic pressure mediate changes in peritubular cap-
illary fluid transfer to maintain GTE, since the constant filtration
fraction dictates essentially constant peritubular capillary oncotic pres-
sure. In this regard, Kon et al, in experimental manipulations of
peritubular capillary plasma flow rate, demonstrated that the peritubu-
lar capillary surface area which determines transcapillary fluid ex-
change (presumably by modulating, in part, the number of open
capillaries) is highly sensitive to the rate of plasma flow perfusing the
capillary [116]. Thus, both glomerular filtration and peritubular capil-
lary fluid transfer occur in a plasma flow-dependent manner, assuring
the proportionality between GFR and peritubular capillary fluid uptake.
Mechanism of the disruption of GTB by angiotensin II. The effect of
endogenous Ang 11 to raise fractional proximal reabsorption in rats with
congestive heart failure indicates that Ang II has a unique capacity to
disrupt GTB. The direct effect of Ang II on Na/H antiporter activity
(hence independent of GFR) allows the achievement of a greater
transepithelial bicarbonate concentration gradient, which limits the net
bicarbonate transport, thereby promoting an increase in fractional
transepithelial fluid reabsorption. Ang II also acts to raise peritubular
transcapillary fluid transfer per given GFR. Ang II's effect on the
efferent arteriole ensures a high filtration fraction, thereby setting up net
peritubular capillary Starling forces favorable for fluid movement into
the capillary [138]. The high oncotic pressure tends to offset the low
plasma flow-induced reduced peritubular capillary surface area, which
would otherwise decrease fluid uptake in parallel with reduced GFR
(hence maintenance of GTB). Thus, Ang II's action on the efferent
arteriole promotes an increase in fractional peritubular transcapillary
fluid uptake. Of interest, high peritubular oncotic pressure was shown
in isolated proximal tubules to induce activation of Na/Cl transport,
as well [139]. Overall, therefore, Ang II's antidiuretic effect is attribut-
able to its ability to disrupt GTB, which in turn stems from its unique
capacity to raise fractional reabsorption by acting on both tubular and
peritubular mechanisms. Of note, the diureses which are often seen
following Ang II administration appear to occur also under orchestrated
adjustments in both tubular (reduced Na/H antiporter activity) and
peritubular capillary (reduced oncotic pressure) transport mechanisms.
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expected to result in reduced peritubular capillary fluid uptake
compatible with the maintenance of glomerulotubular balance
(Fig. 3).
Studies by Harris, Thomas and Morgan, utilizing shrinking
split droplet micropuncture combined with simultaneous capil-
lary perfusion, indicated that atrial natriuretic peptide inhibits
angiotensin Il-induced proximal reabsorption [135]. Garvin
found a similar effect in the isolated perfused rat proximal
straight tubule and suggested that cGMP would inhibit Ang
Il-induced stimulation of proximal reabsorption [136]. In con-
trast, Liu and Cogan did not detect any inhibition by ANF in
vivo [137].
The intracellular signal transduction pathways by which Ang
II modulates proximal tubule functions are not completely
understood. As in the liver and other cells, there is evidence
that in the proximal tubule Ang II is coupled to a pertussis
toxin-sensitive G1, and that addition of Ang II inhibits adenylate
cyclase activity and cAMP accumulation [95]. Since cAMP
inhibits proximal tubule Na/H exchange, lowering cAMP
levels appears to be one mechanism by which Ang II stimulates
proximal tubule bicarbonate reabsorption [138]. In addition,
Liu and Cogan [139] and Wang and Chan [1121 have suggested
that activation of protein kinase C may also serve to stimulate
proximal tubule reabsorption. Although Baum and Hays previ-
ously found that protein kinase C activation inhibited bicarbon-
ate reabsorption in isolated perfused rabbit proximal tubule
[140], Wang and Chan have recently reported that phorbol
ester-induced stimulation of proximal tubule bicarbonate reab-
sorption is time dependent, with prolonged exposure leading to
inhibition [112]. It should be noted that in suspensions of rat and
mice proximal tubules, relatively high concentrations of Ang II
(>10 M) were required to stimulate phosphoinositide hydrol-
ysis [141]. Similarly in cultured rabbit proximal tubule cells,
Ang lI-induced increases in intracellular calcium were only
observed at concentrations > 5 x 10 M [142]. Recent prelim-
inary observations by Romero, Douglas and Hopfer have
suggested that the inhibition of proximal tubule reabsorption
seen with high concentrations of Ang II may be mediated by
generation of cP45O arachidonate metabolites [143].
Early micropuncture studies suggested that Ang II might also
have a distal site of action to inhibit reabsorption [1441. Distal
nephron segments also possess specific Ang II binding sites,
although at a lower density than in the proximal tubule [145].
No recent studies have addressed this issue. Of note is the fact
that medullary interstitial cells in culture can be stimulated by
Ang II to produce prostaglandins [146]; it is, therefore, possible
that arachidonate metabolites may also mediate distal tubular
effects of Ang II. Angiotensin has been shown to exert a tonic
vasoconstrictive effect on medullary vasa recta blood flow as
discussed earlier, although it does not appear to exert dominant
vasoconstrictive influence upon this vasculature [147]. Of inter-
est, unlike the glomerular microcirculation, prostaglandins ap-
pear to exert an independent tonic vasodilatory effect on vasa
recta to offset the vasoconstriction. However, increased Ang II
levels do appear to further stimulate vasa recta prostaglandin
production, since medullary vasoconstriction induced by cyclo-
oxygenase inhibition is augmented in the presence of concom-
itant angiotensin II inhibition [147].
Cell growth and hypertrophy
It has been recognized for some time that constrictive agents
and growth factors share many common features. Thus, vaso-
constrictors and some growth factors have common intracellu-
lar signaling mechanisms, while PDGF and other growth factors
have vasoconstrictor actions [148, 149]. Prototypically, both
Ang II and PDGF induce phospholipase C-mediated breakdown
of phosphatidylinositol bisphosphate (PIP2) to yield inositol
trisphosphate (IP3) and diacylglycerol [150, 151]. Moreover,
both stimulate Na influx in vascular smooth muscle cells
through the amiloride-sensitive Na/H exchange, resulting in
intracellular alkalinization [152, 153]. However, unlike PDGF,
Ang II does not have mitogenic potential in vascular smooth
muscle cells [154]. Thus, whereas Ang II (ED50 = 1.5 x iO M)
has been shown to stimulate 3H-thymidine incorporation into
DNA and cell proliferation in monolayer cultures of bovine
adrenocortical cells [155] and to induce c-fos mRNA [156] in rat
aortic vascular smooth muscle cells [157], it has been shown to
have little effect on DNA synthesis in smooth muscle or
endothelial cells [158, 159], except for those cells freshly
harvested from neonates [160]. Of note, however, exposure of
cultured smooth muscle cells to Ang II results in a substantial
increase in leucine incorporation and total cellular protein
content [15, 161], attesting to its potent capacity to promote
vascular cell hypertrophy. In vascular smooth muscle, Ang II
has also been shown to stimulate S6 kinase activity, which has
been proposed as an important regulatory mechanism of protein
synthesis [162]. Direct hypertrophic actions of angiotensin II
have also been supported by in vivo studies using angiotensin
converting enzyme inhibitors (ACEI) [163—167]. ACE! in vivo
prevented myointimal proliferation after vascular injury [1641.
Abnormal increases in DNA synthesis within the vasculature
have recently been documented prior to the development of
systemic hypertension in rat models of two-kidney Goldblatt
hypertension, and treatment of rats with antimitotic agents or
ACE! [168] effectively prevented the abnormal DNA synthesis,
vascular hypertrophy, and the development of systemic hyper-
tension [165]. Studies in some settings have shown that the
effect of antihypertensive drugs on peripheral vascular hyper-
trophy is independent of their effect on systemic blood pressure
[166, 167]. Thus, in a study of hypertensive cardiac hypertro-
phy, only ACE! was found to prevent and even reverse the
cardiac hypertrophy while equipotent antihypertensive dosages
of calcium channel blockers and hydralazine had no effect [1661.
In addition to its direct vasoconstrictor actions, therefore, Ang
II's capacity to induce hypertrophy in peripheral resistance
vessels may be an important component in the development of
some forms of arterial hypertension.
A direct hypertrophic effect of Ang II has also been demon-
strated in glomerular cells. Thus, exposure of cultured rat
mesangial cells to i0 M Ang II has been shown to increase
their total protein content [1691. However, as in non-renal
vascular smooth muscle cells [170], Ang II did not have a
mitogenic effect on the mesangial cells. The hypertrophic effect
of angiotensin II on glomerular cells has also been demon-
strated in vivo. Thus, administration of ACE! in rats from early
stages of life resulted in a marked attenuation of maturational
growth of glomerular structure and function without interfer-
ence of somatic growth [163]. In addition to the maturational
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growth of glomeruli, other forms of hypertrophy have also been
shown to be sensitive to ACEI. Chronic oral administration of
ACE! in subtotal nephrectomized animals has been shown
repeatedly to attenuate markedly not only the development of
glomerular sclerosis, but also the marked hypertrophy which
precedes sclerosis [171]. Similarly, glomerular hypertrophy
characteristically seen during the development of diabetic
nephropathy in rats has also been shown to be attenuated
markedly by ACEI [35]. Of interest are recent findings by
Rosenberg, Chmielewski and Hostetter in their study of dietary
protein intake (1721. Increased dietary protein intake, which is
known to induce hypertrophy of the glomerulus [1731, has been
shown to increase renal renin mRNA [172]. Moreover, in their
subsequent preliminary study, they found that intrarenal arte-
rial infusion of Ang II led to activation of early growth response
genes, namely c-fos and Egr-1, in the kidneys [1741.
Whether angiotensin II also acts as a hypertrophic agent upon
renal tubular cells is still unclear. Although preliminary studies
by Fine, Badie-DezFooly and Chaudhari suggested that Ang II
did induce hypertrophy in cultured rabbit proximal tubule cells
[175], later studies by this group did not report any hypertrophic
effect, although Ang II was shown to augment EGF-induced
mitogenesis in these cells [142]. More recently, there has been
a report that Ang II stimulates protein synthesis and hypertro-
phy without stimulating proliferation in cultured mouse proxi-
mal tubule cells [176]. Ang II also stimulates S6 kinase activity
in cultured rabbit proximal tubule cells [177].
It should be noted that, in certain unusual circumstances,
Ang II may in fact act, presumably indirectly, as an antihyper-
trophic mediator. An eight week follow-up of partial unilateral
ureteral obstruction in newborn guinea pigs (nephronogenesis is
completed in guinea pigs at the time of birth) revealed that
obstructed kidneys are characterized by a defective matura-
tional increase in both kidney weight and renal blood flow. They
were further characterized by a significantly depressed number
of perfused glomeruli, as well as small glomerular size [178] and
increased renin content. When animals were given an angioten-
sin I converting enzyme inhibitor from the onset of ureteral
obstruction, the number of perfused glomeruli was found to be
markedly elevated over untreated obstructed kidneys [178].
The glomerular volume of the obstructed kidneys was also
increased by ACE! and reached a level comparable to that of
non-obstructed control kidneys. Overall, the studies in new-
born guinea pigs suggest that a heightened local level of
angiotensin II induced by ureteral obstruction in the neonatal
period results in impairment of maturational growth and perfu-
sion of the glomerulus.
Matrix accumulation and sclerosis
In several different animal models of progressive glomerular
sclerosis [35, 89, 179—181], administration of orally active ACE!
effectively attenuated or even reversed development and ad-
vancement of sclerotic lesions. In view of the multifactorial
mechanisms involved in ACEI actions—mechanisms that are
separate from a specific inhibitory effect on the conversion of
angiotensin I to LI—these observations cannot be taken as
incontrovertible evidence for a role for Ang II in the pathogen-
esis of glomerular sclerosis. Further confounding the issue is
the fact that both these animal models and humans lack
evidence for a role of circulating renin-angiotensin [34, 182—
184]; it remains uncertain whether local activation of this
system is more relevant pathophysiologically. Recent investi-
gations have, therefore, been focused on identifying (1) whether
or not angiotensin II actions are locally enhanced and (2)
whether or not angiotensin II can act directly on glomerular
cells to promote accumulation of extracellular matrices. In this
regard, the most recent assessment of this system at the level of
gene expression indicates that, at least in some experimental
settings linked to glomerular sclerosis, the renin-angiotensin
system is locally activated [47, 173]. Thus, increased dietary
protein intake, which is known to accelerate the progression of
glomerular sclerosis in various models, has been shown to
increase renal renin mRNA [72]. In view of the variety of
known glomerular effects of angiotensin II, any action in
promotion of mesangial matrix accumulation may be indirect,
such as, affecting local glomerular circulatory dynamics, pro-
moting macromolecular entrapment by mesangial cells, and
even centrally activating the sympathetic nerve. While it is
likely that local cytokines and growth factors are ultimately
involved in each of these processes, results of a recent study
raise the possibility that Ang II can directly promote the
accumulation of mesangial matrix. In cultured rat mesangial
cells exposed to iO M, Ang II increased both collagenous and
non-collagenous protein production, as assessed by the amount
of radiolabelled proline which had been incorporated into the
collagenase-digestable cell component, along with total protein
content. In contrast, endothelin stimulated cell proliferation but
did not affect collagen production [169].
The effect of Ang II in the promotion of collagen/collagenous
materials is not confined to mesangial or vascular smooth
muscle cells. In fact, a recent series of studies conducted by
Wolf, Killen and Neilson [185] demonstrated that Ang II, at the
concentration of 108 M, stimulates secretion of type IV colla-
gen from murine proximal tubular epithelial cells in culture
through a reduction in intracellular cAMP. This observation
echoes the findings in in vivo studies that administration of
angiotensin II converting enzyme inhibitors effectively attenu-
ates/prevents not only glomerular but also tubulointerstitial
damages which occur in animal models of progressive renal
failure [186].
Chemoattraction of circulating cells
There is a growing body of evidence indicating that Ang II
affects circulating cells. Ang II receptors have been demon-
strated on human monocytes [187]. Macrophages isolated from
granuloma in schistosoma infection were shown to have Ang II
receptors that are linked to adenylate cyclase activity [188].
Moreover, Ang II stimulated chemotaxis of human mononu-
clear cells [189]. Adhesion and/or entrapment within the vessel
are initial obligatory steps for the circulating polymorphonu-
clear cells (PMN) in exerting cytotoxicity within the tissues.
Due to their relatively large dimension, PMNs are deformed on
their passage through the capillary network by forming a large
contact area with the capillary endothelium. Mathematically,
the force required for dislodging circulating cells trapped in a
capillary lumen has a direct relationship with the adhesiveness
between the interfacing PMN and endothelial cell surfaces and
a reciprocal relationship with the lumen diameter to the third
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power [190]. In situ, various PMN chemoattractants exert their
action through affecting either or both of these two parameters
by acting on PMNs [191] and/or endothelial cells.
In view of the observation described earlier that Ang II can
decrease the dimension of the glomerular capillary, the possi-
bility was tested that a high local level of Ang II may enhance
PMN entrapment [19]. Ang 11(120 ng/kg/hr) was continuously
infused with a micropipette into a first-order branch of the renal
artery, followed by perfusion-fixation. Morphologic examina-
tion revealed that PMNs activated in vivo by FMLP (formly-
met-leu-phe) which were then injected into the main renal
artery were trapped by more than twofold in glomeruli exposed
to Ang II compared to non-exposed glomeruli. Likewise, mi-
crospheres injected into the main renal artery during Ang II
infusion were increased by 50% in exposed glomeruli. Thus, it
appears that the reduced capillary lumen diameter, as induced
by Ang II can play an important role in PMN attraction to the
glomerulus by promoting the initial event of neutrophil entrap-
ment.
A study by Farber, Center and Rounds [192] deals with yet
another potential mechanism through which Ang II may act as
a PMN chemoattractant. In their study, cultured bovine and
human endothelial cells exposed to Ang II were shown to
release PMN chemoattractant activity, which was inhibitable
by saralasin, Thus, Ang II may play an important role in the
early events of tissue inflammation, during which a high local
level of Ang II may act as a crucial chemoattractant [193].
Interaction with other agents
Although angiotensin II, acting through membrane receptors,
directly affects vascular smooth muscle, mesangial cells, and
proximal tubule cells, other effects are mediated by interactions
with eicosanoid metabolites, neurotransmitters, and other pep-
tide hormones. As previously mentioned, Ang II is known to
activate phospholipase A2 in the smooth muscle and mesangial
cells with resultant increases in prostaglandin production. Va-
sodilatory prostaglandins are known to modulate the glomerular
hemodynamic effects of Ang II; prostaglandin's modulatory
effects upon Ang Il-sensitive glomerular cell growth and matrix
production have been suggested but remain speculative [170].
In addition to the possible antagonistic effect of angiotensin II
upon the proximal tubule reabsorption by ANF (mentioned
above), Ang II's effects on the proximal tubule may also be
modulated by other peptide hormones. In this regard, Ang II
and selective a2-adrenergic agonists act synergistically to stim-
ulate Na/H exchange, while the Ang Il-induced stimulation
is significantly inhibited by either PTH or dopamine [92].
Furthermore, bradykinin can induce heterologous desensitiza-
tion of Ang II [183]. Finally, Ang II acts synergistically with
EGF to stimulate proliferation of cultured proximal tubule cells
[1041.
Studies have indicated an interaction between the renin-
angiotensin system and the renal sympathetic nervous system
in the mediation of glomerular hemodynamics. It has been
found that angiotensin II is a necessary factor in sympathetic
nerve-induced vasoconstriction because salarasin or angioten-
sin converting enzymes prevent renal nerve stimulation-in-
duced alterations in glomerular hemodynamics [41, 1831. Con-
versely, following renal denervation, glomerular pressor
responses to angiotensin II administration have been aug-
mented, presumably due to increases in glomerular Ang 11
receptors [194—196].
It has also been suggested that ANF and angiotensin II are
mutually antagonistic in their responses to vascular smooth
muscle and mesangial cells. However, this appears not to be
specific for angiotensin II, since other vasoconstrictors can
inhibit ANF's actions and vice versa [117]. In contrast, there
does appear to be a specific interaction between ANF and
angiotensin II in the proximal tubule since, as mentioned
previously, ANF does not directly inhibit proximal tubule
function but does inhibit Ang Il-stimulated reabsorption [1351.
In summary, this article reviews the recent work on the
physiological and pathophysiological actions of angiotensin II
in the kidney. These recent research endeavors have uncovered
a number of biological actions of angiotensin II and have
expanded our knowledge of the kinetics and biochemical mech-
anisms underlying these actions.
However, further studies are required to firmly establish the
significance of these actions in the in situ setting, particularly in
the newly appreciated area of great interest for angiotensin II,
namely growth and development of renal tissues. These efforts
will, no doubt, identify new frontiers for angiotensin II actions
and unify the seemingly unrelated actions of angiotensin II
documented here.
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